title: Isolated lung perfusion for pulmonary metastases.
abstract: Isolated lung perfusion is an experimental surgical technique evaluated for the delivery of high-dose chemotherapy to improve 5-year survival after pulmonary metastasectomy. Extensive experimental work in animal models has demonstrated superior pharmacokinetics and efficacy compared with systemic therapy. Phase I clinical trials of isolated lung perfusion found a maximum tolerated dose**** of TNF-alpha, doxorubicin, cisplatin, and melphalan, whereas the combination of isolated lung perfusion with a complete metastasectomy was feasible. The combination of isolated lung perfusion and regional lung perfusion techniques needs further investigation.
authors.affiliation: Department of Thoracic and Vascular Surgery, University Hospital Antwerp, Wilrijkstraat 10 B-2650, Edegem, Belgium. jeroen.hendriks@uza.be
authors.forename: Jeroen M H
authors.initials: JM
authors.lastname: Hendriks
authors.forename: Bart P
authors.initials: BP
authors.lastname: Van Putte
authors.forename: Marco
authors.initials: M
authors.lastname: Grootenboers
authors.forename: Wim J
authors.initials: WJ
authors.lastname: Van Boven
authors.forename: Franz
authors.initials: F
authors.lastname: Schramel
authors.forename: Paul E Y
authors.initials: PE
authors.lastname: Van Schil
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D023421:Models, Animal; D051381:Rats; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D014409:Tumor Necrosis Factor-alpha